Recent clinical trials reporting on hSSTR2-positive tumors (i) assessed the diagnostic agents in different types of cancer that partly express SSTR2 (NCT04298541), (ii) optimized imaging protocols, and (iii) assessed the potential of [177Lu]Lu-DOTATATE in GEP-NET (NCT02936323) and SSTR2-positive breast cancer (NCT04529044). Here, SSTR2 is linked to breast carcinoma.